Scinnohub Pharmaceutical Co., Ltd.
Clinical trials sponsored by Scinnohub Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to cut bleeding in knee replacements Results expected Dec 2026 (estimated)
- New hope for thalassemia: drug trial targets anemia without transfusions Results expected Mar 2027 (estimated)
- New pill targets Hard-to-Treat cancers in early trial Results expected Jun 2027 (estimated)
-
New drug aims to cut bleeding in knee replacements
Disease control Recruiting nowThis study tests an experimental drug called BT-114143 to see if it can reduce blood loss during knee replacement surgery better than a standard treatment. About 270 adults with osteoarthritis who need a knee replacement will take part. Participants will receive either a high or …
Phase 2 • Sponsor: ScinnoHub Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New injection aims to tame heavy periods
Symptom relief Recruiting nowThis early-stage trial tests an injectable drug called BT-114143 in 39 women with abnormal uterine bleeding. Participants receive different doses twice daily for three days to see if it safely reduces bleeding. The study also checks for side effects and changes in blood clotting.
Phase 1 • Sponsor: ScinnoHub Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC